ACRS
Aclaris Therapeutics Inc
5.40$
+2.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.6% | -11.8% | -7.5% | +13.2% | +20.8% | -10.1% | -4.5% | -7.2% | -8.6% | +23.8% | -9.6% | |
| – | +4.7% | +5.0% | -13.1% | +12.5% | -4.8% | -13.6% | -4.2% | -3.5% | +50.5% | -27.2% | -11.3% | |
| – | +2.1% | -10.1% | -36.3% | +108.7% | -48.4% | +23.6% | -16.3% | -0.6% | -21.0% | +43.6% | -33.1% | |
| – | +15.6% | +7.6% | -13.3% | +15.0% | -11.1% | -7.3% | -5.2% | -3.9% | -5.4% | +16.2% | -13.1% | |
| – | -13.9% | +25.2% | -12.9% | +5.5% | -7.3% | -21.4% | -22.4% | +2,312.4% | +18.9% | -13.5% | +29.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -96.1% | – | – | – | – | – | – | – | – | – | – | |
| – | -35.1% | -20.3% | -15.0% | +91.7% | +24.0% | -16.6% | +6.3% | -3.4% | +3.5% | -4.0% | +0.1% | |
| – | +13.3% | -35.1% | -21.9% | +20.0% | +67.9% | -31.9% | +24.8% | -4.5% | +11.8% | -4.5% | +3.2% | |
| – | +37.4% | +18.1% | -10.7% | +3.6% | +3.4% | +3.5% | +3.4% | +3.5% | +3.4% | +3.3% | – | |
| – | -8.0% | +21.8% | -32.8% | +5.4% | -38.8% | +35.5% | +38.4% | +4.4% | +43.2% | +12.0% | +5.3% | |
| – | +0.5% | -9.6% | -5.8% | -2.7% | +19.5% | -7.4% | -8.6% | -8.8% | -14.2% | +39.4% | -13.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.1% | +0.3% | +0.3% | +0.1% | +33.5% | +28.4% | +0.2% | +0.0% | +0.0% | +5.0% | +10.8% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.